high mobility group nucleosome binding domain 1 pseudogene 28Genealiases: []
Q-omics provides the consensus-scored HMGN1P28 profile across patient tissues and cancer cell-line models. HMGN1P28 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HMGN1P28 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, HMGN1P28 RNA expression shows 7,150 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BRCA, and ACC as cancer lineages where HMGN1P28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN1P28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN1P28 survival associations across molecular data types. HMGN1P28 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN1P28 RNA expression–survival associations across cancer types. High HMGN1P28 expression shows unfavorable associations in UVM, BRCA, SKCM and LIHC, but favorable associations in DLBC and COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HMGN1P28 RNA expression.
This table summarizes HMGN1P28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN1P28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN1P28 shows lower tumor expression in COAD and higher tumor expression in BRCA, LUSC, KIRP, LUAD and KICH. The BRCA box plot shows higher HMGN1P28 RNA expression in tumor versus normal tissue (log2 FC = +0.085, t-test p = .001).
This table shows molecular features associated with HMGN1P28 in patient tissues and cancer cell lines. In patient samples, HMGN1P28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
